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ABSTRACT
Tissue-specific effects of 17β-estradiol are delivered via both estrogen receptors and 
microRNAs (miRs). Menopause is known to affect the whole-body fat distribution in women. 
This investigation aimed at identifying menopause- and hormone replacement therapy 
(HRT)-associated miR profiles and miR targets in subcutaneous abdominal adipose tissue 
and serum from the same women. A discovery phase using array technology was performed 
in 13 women, including monozygotic twin pairs discordant for HRT and premenopausal 
young controls. Seven miRs, expressed in both adipose tissue and serum, were selected 
for validation phase in 34 women from a different cohort. An age/menopause-related 
increase of miRs-16-5p, -451a, -223-3p, -18a-5p, -19a-3p,-486-5p and -363-3p was found 
in the adipose tissue, but not in serum. MiR-19a-3p, involved in adipocyte development 
and estrogen signaling, resulted to be higher in HRT users in comparison with non-users. 
Among the identified targets, AKT1, BCL-2 and BRAF proteins showed lower expression 
in both HRT and No HRT users in comparison with premenopausal women. Unexpectedly, 
ESR1 protein expression was not modified although its mRNA was lower in No HRT users 
compared to premenopausal women and HRT users. Thus, both HRT and menopause 
appear to affect adipose tissue homeostasis via miR-mediated mechanism.
INTRODUCTION
Human aging is a lifelong process characterized 
by a dynamic phenotype that changes over time, also 
associated with sex hormone differences in men and 
women [1]. During menopausal transition, concentration 
of circulating 17β-estradiol (E2) decreases concomitantly 
with an increase in follicle-stimulating hormone (FSH). 
Declining amounts of ovarian E2 lead to changes in the 
distribution of body fat [2] emphasizing the importance 
of ovarian E2 in regulating the lipid metabolism. The 
effects of E2 in adipose tissue are likely mediated 
through estrogen receptors among them ESR1 is known 
to affect whole-body metabolism as well as adipocyte 
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cell growth and differentiation [3, 4]. Postmenopausal 
women adopting E2-based hormone replacement therapy 
(HRT) have healthier adipokine/cytokine profile and less 
centrally located body fat than women not using HRT [5, 
6, 7]. This evidence is relevant since adipose tissue is 
metabolically active and, owing to its secretory activity, 
it is one of the main contributors to the crosstalk among 
different tissues [8]. Furthermore, the role of adipose 
tissue in human aging is central due to its influence on 
sustaining the pro-inflammatory microenvironment, 
the main premise underlying “inflammaging” and its 
propagation mechanisms [9, 10]. However, adipose 
tissue is not only responsive to fluctuations in the 
systemic levels of hormones, but it actively produces 
and secrets multitude of molecules including E2, other 
hormones, inflammatory factors and microRNAs 
(miRs).
MiRs are small RNAs that contribute to gene 
regulation by binding to their mRNA targets, a process 
that induces mRNA cleavage or seizure and, eventually, 
a possible reduction in the abundance of the functional 
target protein. Many of the miRs expressed by adipose 
tissue take part in adipogenesis and lipid homeostasis [11, 
12, 13, 14]. Aging affects adipose tissue miR expression 
in humans [15], thus leading to alterations in miR target 
abundancy either locally or at systemic level eventually 
far from the site of exocytosis [16]. We have previously 
shown that specific circulating miRs [17, 18] and skeletal 
muscle miRs [19] of pre- and postmenopausal women 
were associated with serum E2 levels. These findings 
indicate that sex steroid hormones are part of miR-
mediated mechanisms in aging women.
The aim of this study was to investigate the 
epigenetic changes, i.e. miR profiling expression, 
associated with age/menopause and HRT in two different 
specimens, i.e. blood serum and white adipose tissue, 
obtained from the same donors. Discovery phase was 
performed using miR card arrays on samples from 
premenopausal women (none used hormonal medication) 
and postmenopausal monozygotic (MZ) twin pairs 
discordant for HRT. Validation phase was performed in 
a larger different cohort of premenopausal women and of 
unrelated postmenopausal HRT and No HRT users. The 




Two different samples and data sets originating 
from 1) the SAWEs and 2) miRBody studies were 
analyzed (Figure 1A). The SAWEs study consists of 
a cross-sectional design with premenopausal women 
(Pre) without any E2-containing hormonal treatments, 
and a co-twin design of postmenopausal MZ twin 
sister pairs with approximately 7 years of E2-based 
HRT discordance (HRT and No HRT users), i.e. one 
sister was a current HRT user and the other had never 
used HRT. MiRBody is a cross-sectional study with 
a postmenopausal cohort of unrelated women who 
were age-matched with the SAWEs MZ twins and 
formed two groups, one using and the other not using 
HRT. The SAWEs samples were miR- profiled. The 
miRBody samples (postmenopausal HRT and No HRT 
women) and SAWEs samples (premenopausal women) 
were available for the validation of the profiling data. 
Figure 1B shows the scheme of comparisons among the 
identified three groups.
Table 1 shows anthropometric data, serum 
inflammatory markers and hormone levels measured in the 
different data sets among the groups and Supplementary 
Table 1 reports the clinical data. No differences in body 
composition measures or inflammatory markers were 
observed among the groups. Serum E2 and FSH levels 
differed, as expected, most significantly between the 
premenopausal women and No HRT users. In fact, E2 
showed the highest values in the premenopausal women 
and the lowest values in the postmenopausal non-users 
and vice versa for FSH. Comparisons were also performed 
between the SAWEs and miRBody participants. The 
E2 levels of the postmenopausal No HRT group in the 
miRBody study were higher than those of the SAWEs No 
HRT women (p < 0.001) and the E2 levels of the SAWEs 
No HRT women differed significantly from the miRBody 
HRT women (p < 0.001). The differences between the 
No HRT groups might in part be due to the different 
methods used to analyze the E2 levels in these two studies 
(see methods). Otherwise, no group differences between 
postmenopausal SAWEs and miRBody women were 
detected.
miR profiling and discovery phase
TaqMan human card array containing 377 miRs for 
profiling in 13 women (including twin pairs) was used. Ten 
subcutaneous adipose tissue and 13 serum samples obtained 
from the premenopausal women and postmenopausal MZ 
twin sister pairs of the SAWEs study were analyzed. In total, 
203 miRs in the adipose tissue and 92 miRs in the serum 
(Figure 2A) were detected. Three types of comparisons were 
performed as follows: 1) Postmenopausal No HRT group vs. 
premenopausal women in order to identify hormonal aging-
associated differences. 2) Postmenopausal HRT group vs. 
premenopausal women in order to identify hormonal aging-
associated differences along with E2-supplementation. 3) 
Postmenopausal HRT group vs. postmenopausal No HRT 
group in order to identify HRT-associated differences at 
the same genetic background. MiRs with fold change (FC) 
values ≥ 1.9 are shown in Figure 2A. A list of all the FCs 
obtained is specified as supplementary data (Supplementary 
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Figure 1: Recruitment of the participants and scheme of experimental design.  Panel (A) shows the flowchart of the 
recruitment process of the two different data sets used in the study. Panel (B) shows the investigated groups and comparisons. Pre = 
premenopausal women, No HRT = postmenopausal women without estrogen-based hormone replacement therapy, HRT = postmenopausal 
women with estrogen-based hormone replacement therapy. See also Supplementary Table 1.
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Table 2). The experimental design (Figure 1B) and miR 
filtering procedure, as detailed in Figure 2A, yielded the 
following results: Age associations without HRT (No HRT 
vs. Pre) were defined for 16 and 23 miRs in adipose tissue 
and serum, respectively. Age associations with HRT (HRT 
vs. Pre) were defined for 24 and 8 miRs in adipose tissue 
and serum, respectively. HRT associations (HRT vs. No 
HRT) were defined for 31 and 27 miRs in adipose tissue 
and serum, respectively.
Ingenuity Pathway Analysis (IPA) was performed 
to identify the potential biological processes and possible 
interactions with the profiled adipose tissue and serum-
derived miRs taking into account all the comparisons 
among the groups (Figure 2B). The analyses predicted 
differences in up- or downregulated biological functions 
between adipose tissue and serum. In No HRT vs. Pre 
-comparison biological processes, as necrosis, apoptosis 
and DNA damage were predicted to be affected. In 
HRT vs. No HRT comparison, the predicted pathways 
were cell proliferation of hepatoma cell lines and DNA 
damage. HRT vs. Pre -comparison showed no statistically 
significant predictions in any biological processes. The 
identified biological processes revealed opposite patterns 
in the adipose tissue and serum samples.
Validation of the miR profiling
MiR profiling was validated in 34 women by means 
of RT-qPCR. Sixty-seven samples (33 adipose tissues, 34 
serum) from the premenopausal women (SAWEs) and the 
independent clinical cohort of postmenopausal HRT and No 
HRT users (miRBody) were analyzed. We selected those 
miRs detected in all measured samples. Further, we selected 
6 statistically relevant miRs (FC ≥1.9) expressed in both 
adipose tissue and serum, obtained from the same donor. 
Interestingly, these selected miRs (miR-16-5p, miR-451a, 
miR-223-3p, miR-18a-5p, miR-19a-3p, miR-486-5p) were 
by chance expressed in the opposite directions considering 
adipose tissue and serum for each group comparison. One 
additional miR, showing the highest FC in adipose tissue 
(miR-363-3p), was also selected, as reported in Figure 2A. 
In the adipose tissue (Figure 3) the main results were the 
following: miRs-16-5p, -451a, -223-3p, -18a-5p, -19a-3p, 
-363-3p, and miR-486-5p were more expressed with age/
menopause (No HRT vs. Pre: p < 0.001; p < 0.001; p = 0.003, 
p = 0.003; p = 0.006; p < 0.001; p = 0.002, respectively). 
These results were mainly in accordance with miR profiling 
(except miR-223-3p and miR-363-3p). The same miRs were 
confirmed to be more expressed with age and HRT use (HRT 
















Age (yrs)# 32.9±3.3 57.4±1.5* 57.4±1.5* 57.7±2.9* 58.8±3.0*
Years on HRT - 8.4±4.7 - 6.6±6.3 -
BMI (kg/m2) 27.1±5.7 26.6±3.3 27.3±5.6 27.7±4.6 27.9±3.8
Fat % 32.3±9.2 31.6±7.3 33.3±9.3
LBM (kg) 45.5±4.6 45.1±2.0 44.2±4.0
CRP (mg/l) 1.4±1.7 1.3±1.1 1.3±0.7 2.4±2.2 (n=15) 3.5±3.8 (n=15)
HGB (g/l) 136.5±7.1 146.0±8.1*$ 138.8±12.4 138.7±10.1 (n=12) 135.0±10.1 (n=11)
WBC (e9/l) 5.7±1.3 5.9±1.1 5.7±1.8 6.4±1.5 (n=12) 6.1±1.8 (n=11)
E2 (pmol/l)# 355.4±288.5 250.4±296.4*† 23.8±10.6* 284.4±177.4$† 118.4±46.9*†
FSH (IU/l)# 6.0±2.3 39.8±32.0* 75.1±46.5* 32.9±24.6* 58.2±28.4*
See also Supplementary Table 1.
Results are shown as mean ± S.D. For parametric variables, independent samples T-test was used to compare the 
postmenopausal groups with the premenopausal group and to compare mirBody postmenopausal HRT group with the No 
HRT group, while paired samples T-test was used to compare the SAWEs HRT women with the No HRT co-twins. For non-
parametric variables, #Mann Whitney U test was used to compare the postmenopausal groups with the premenopausal group 
and to compare mirBody postmenopausal HRT group with the No HRT group, while Wilcoxon matched pair signed-rank 
test was used to compare the SAWEs HRT women with the No HRT co-twins. Significant comparisons between the studied 
groups: *P<0.05 compared to the Premenopausal group; †P<0.05 compared to the SAWEs Postmenopausal No HRT group; 
$P<0.05 compared to the miRBody No HRT group. BMI: body mass index, LBM: lean body mass (fat free), CRP: high 
sensitivity C-reactive protein, HGB: hemoglobin, WBC: white blood cell count, E2: 17β-estradiol, FSH: follicle-stimulating 
hormone.
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Figure 2: MiR profiling of adipose tissue and serum-derived miRs. (A) Discovery phase of the miRs performed on arrays for 
both tissues (FC ≥ ±1.9). Numerical FC values for the comparisons are specified as supplementary data (Supplementary Table 2). All the 
comparisons, i.e. No HRT vs Pre, HRT vs Pre, HRT vs No HRT, were taken into account in both 10 adipose tissue (on left) and 13 blood 
serum samples (on the right). Venn diagram presents the numbers of all the detected miRs and those chosen for RT-qPCR validation. (B) 
IPA comparison analyses were performed between adipose tissue and serum miRs in each comparison (FC ≥ ±1.9, Z-activation score ≥ 
± 2.0). Results show the differences between the two tissues in terms of diseases and biological functions. Orange indicates up- and blue 
downregulation.
Oncotarget2284www.impactjournals.com/oncotarget
vs. Pre: p = 0.002; p = 0.014; p = 0.009; p = 0.024; p = 0.036; 
p = 0.039, respectively), except miR-19a-3p. These results 
were not in accordance with miR profiling excluding the 
case of miR-16-5p. MiR-19a-3p resulted to be sensitive to 
HRT when No HRT women, having E2 levels lower than 
110 pmol/l were considered, thus excluding No HRT with 
highest E2 values. E2 concentration of 110 pmol/l represented 
the lowest E2 value found in the HRT group. It was essential 
to avoid overlapping between HRT and No HRT groups in 
terms of E2 serum values to find differences between the two 
groups. In fact, the analysis revealed significantly higher 
miR-19a-3p levels in the postmenopausal low-E2 No HRT 
than HRT groups (p = 0.043, Figure 4).
In serum samples of the same women, single 
miR analyses of miRs-16-5p, -451a, -223-3p, -18a-5p, 
-19a-3p, -363-3p, and miR-486-5p by RT-qPCR did not 
confirm data obtained by the miR profiling. No significant 
differences were observed. Therefore, further analyses of 
the miR targets were performed only in adipose tissue.
Adipose tissue miRs associate with age and 
circulating hormones
A clustered correlation heatmap was created to 
determine the associations of the validated adipose tissue 
miRs with age, body mass index (BMI) and circulating 
high sensitivity C-reactive protein (CRP), E2 and FSH 
levels (Figure 5). All the adipose tissue miRs correlated 
positively with age (false discovery rate corrected p-value 
-FDR < 0.05) and all, except miR-223-3p, negatively with 
serum E2 levels (FDR < 0.05). In addition, miR-18a-5p, 
-16-5p and -363-3p showed positive correlations with 
serum FSH levels. None of these miRs were significantly 
associated with BMI or CRP. Numerical details of the 
correlations are specified as supporting information 
(Supplementary Table 3).
mRNA and protein expressions of miR targets in 
adipose tissue
A bioinformatic approach, based on experimentally 
validated and published miR-target pairs, was applied 
for the currently validated miRs (Figure 6A). Thus, the 
common targets considering at least two miRs targeting 
the same mRNA including ESR1, AKT1, BRAF, BCL-
2 and CCND1 were identified (Figure 6B). Both mRNA 
and protein levels were measured in adipose tissue 
samples for all the identified targets (33 mRNA and 15 
protein samples), as described in Figure 7. ESR1, AKT1 
and CCND1 mRNAs were less expressed with aging/
Figure 3: RT-qPCR validation of selected miRs in adipose tissue. * p < 0.05, ** p < 0.01, *** p < 0.001. Pre = premenopausal 
women (n=12), HRT = postmenopausal HRT users (n=9), No HRT = postmenopausal non-users (n=12). Results are shown as mean ± SD. 
Data were normalized by RNU44 expression levels.
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menopause (No HRT vs. Pre; p < 0.001, p = 0.005, p = 
0.003, respectively). At protein level, AKT1, BRAF and 
BCL-2 were significantly less abundant in postmenopausal 
women (p = 0.005, p = 0.003, p = 0.028, respectively). 
AKT1 and CCND1 mRNAs were also less expressed 
with aging/HRT use (HRT vs. Pre; p = 0.023, p = 0.014, 
respectively). At protein level, AKT1, BRAF and BCL-2 
were significantly less abundant in HRT in comparison 
with premenopausal women (p = 0.013, p = 0.020, p = 
0.024, respectively). ESR1 mRNA was found to be more 
expressed with HRT treatment (HRT vs. No HRT; p = 
0.026) whereas at protein level ESR1 values were similar 
in all groups.
DISCUSSION
Aim of the study was to focus on epigenetic changes 
associated with a crucial event of woman’s reproductive 
life, i.e. menopause, when evolution force is predicted to 
decline, accordingly with some theories of aging [20] and 
likely, when aging trajectories move towards either the 
onset of age-related diseases or healthy status preservation 
[21]. To better disentangle the role of estrogen, a group of 
postmenopausal women using E2-based HRT was studied 
along with healthy pre- and postmenopausal women 
without any E2-based medications. MiR expression 
was selected to be a relevant marker for tissue aging 
[22], being also a type of “epigenetic communication” 
among organs and tissues, when blood circulation is 
comprised. In fact, both adipose tissue and serum from 
the same individual were analyzed. Initially, we adopted 
an exploratory miR profiling approach to determine the 
differences of miR expression, assuming causality due 
to aging or menopausal status and/or postmenopausal 
HRT treatment. We detected 203 miRs in the adipose 
tissue and 92 in the serum samples. Functional analysis 
with IPA predicted necrosis, apoptosis and DNA damage-
related biological processes to be the main downstream 
mechanisms affected by these miRs with menopause 
status. The IPA results support the general hypothesis that 
inflammaging is fueled by the age-related production of 
cell debris or misplaced cell-molecules released during 
repair or damage processes, along with circulating miRs 
[23]. Previous data obtained on monozygotic twin pairs 
discordant for HRT showed a correlation between blood 
circulating inflamma-miRs and a pro-inflammatory 
Figure 4: RT-qPCR validation of miR-19a-3p in adipose tissue. Relative expression of miR-19a-3p in all the groups considering 
No HRT women with low E2 level (53.6-99.1 pmol/l) 
* p < 0.05, Pre = premenopausal women (n=12), HRT = postmenopausal HRT users 
(n=9), No HRT = postmenopausal non-users (n= 6). Results are shown as mean ± SD. Data were normalized by RNU44 expression levels.
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cytokine in No HRT but not in HRT group, suggesting 
possible anti-aging effects of HRT [17].
We selected for validation 6 miRs found to be 
present in both the adipose and serum samples with 
opposite trends of expression (considering all the 
comparisons among the three groups of women: miR-
16-5p, miR-451a, miR-223-3p, miR-18a-5p, miR-19a-
3p, miR-486-5p) and the most highly expressed miR 
in adipose tissue (miR-363-3p). In line with the results 
obtained by the profiling, RT-qPCR validation confirmed 
most of the age-menopause associations of miRs increase 
in adipose tissue. We demonstrated that all the selected 
miRs increase with age or menopausal status and the 
same miRs, except miR-19a-3p, were also found highly 
expressed in HRT users, thus suggesting no effect of HRT 
on these selected miRs. Validated miRs were shown to 
target ESR1, AKT1, BCL-2, BRAF and CCND1, thereby 
indicating their role in the regulation of adipocyte cell fate, 
death or proliferation.
Despite the profiling results, the selected miRs were 
not differentially expressed in the serum, suggesting not 
only a specific effect of HRT treatment on adipose tissue, 
but also no relations of age and HRT with the selected 
miRs in the circulation. Validation phase is crucial, 
since card array technology sometimes can produce bias 
especially when studying circulating miRs. Recently, we 
demonstrated that age/menopause and HRT differentially 
modulate the expression of specific miRs shuttled in 
circulating exosomes [18], by means of next generation 
sequencing (NGS). To this regard, the high resolution of 
NGS confirms the absence of changes in the currently 
selected miRs, thus reinforcing the result that hormonal 
Figure 5: Clustered heatmap including the validated adipose tissue miRs and their associations with serum hormones, 
CRP and BMI.  * p < 0.05, * p < 0.05 with FDR correction. The numerical values of the Spearman correlation, P-values and FDR 
corrected P-values are specified as supplementary data (Supplementary Table 2). FSH = follicle-stimulating hormone, CRP = high 
sensitivity C-reactive protein, BMI = body mass index, E2: 17β-estradiol. See also Supplementary Table 3.
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Figure 6: Overall miRs results and their targets involved in estrogen signaling pathway. (A) Overall miRs results considering 
all the comparisons and No HRT women with lower E2 level. (B) Experimentally validated miR-target pairs are bolded and underlined. The 
other miRs indicate putative miR-target pairs. Currently selected targets are highlighted in yellow. Data is obtained from http://diana.imis.
athena-innovation.gr/DianaTools/index.php and http://zmf.umm.uni-heidelberg.de/apps/zmf/mirwalk2/. References for experimentally 
validated miR-target pairs are published [24, 25, 26, 27, 48, 49, 50, 51, 52, 53, 54, 55].
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Figure 7: Relative mRNA expression and protein levels of the miR targets. * p < 0.05, ** p < 0.01, *** p < 0.001. Pre = 
premenopausal women (n
mRNA
=12, nprot=5), HRT = postmenopausal HRT users (nmRNA=9, nprot=5), No HRT = postmenopausal non-users 
(n
mRNA
=12, nprot=5). Results are shown as mean ± SD. In the left column mRNAs and in the right column protein data are reported. mRNA 
data were normalized against GADPH expression levels. In the right column, the upper western blots show the investigated proteins and 
the lower blots show the Ponceau dye (60 kDa) used for normalization procedure.
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aging and HRT have tissue-specific effects that do not 
“propagate” in the blood, and do not affect the level of the 
circulating miRs, at least for those selected.
Importantly, we have shown that miR-19a-3p is 
sensitive to HRT. In fact, HRT women have a level of 
miR-19a-3p similar to younger premenopausal controls, 
while No HRT users, with lower E2 blood levels, have a 
higher expression of miR-19a-3p, suggesting an anti-aging 
effect of HRT in terms of regulation of this miR in the 
adipose tissue.
Of note, miR-19a-3p and -18a-5p have previously 
been shown to target ESR1 [24, 25, 26, 27]. These miRs 
are part of a miR-17-92 cluster, which has been shown to 
participate in the regulation of adipocyte development by 
accelerating preadipocyte differentiation [28]. Our results 
showed the opposite expression patterns between miR-
18a-5p; -19a-3p and ESR1 mRNA target, as expected. 
MiR-17-92 cluster was previously demonstrated to be 
involved in aging process and a decrease of miR-19b was 
shown in various in vitro or ex vivo cell models [29, 30]. 
We observed a trend of miR-19a-3p increase with age/
menopause along with lower serum E2 concentration. 
These apparently opposite trends are likely due both to 
the different type of analyzed tissue/cell and the different 
miR-17-19 cluster members (miR19a vs miR-19b), which 
may have different targets and functions.
Furthermore, our results indicate that miR-223-
3p, -16-5p, -363-3p and -486-5p, which are predicted 
to target ESR1 based on their complementary sequence 
structure, also may contribute to the regulation of ESR1 
expression, owing to their similar expression pattern with 
miR-18a-5p and -19a-3p and negative correlation with 
E2 (except for miR-223-3p) as shown in the hierarchical 
clustering analysis. As expected, the levels of the miRs 
targeting ESR1 have an opposite trend with the amount 
of ESR1 mRNAs in the adipose tissue. Nevertheless, 
ESR1 protein levels appear well preserved in all groups, 
thus suggesting other regulatory layers [31] and the great 
capacity of adipose tissue to maintain the expression of a 
key regulatory receptor. In fact, the expression of ESR1 is 
found different depending on the type and site of adipose 
tissue in the same individual [32] under the same level of 
blood estrogen. These data mean that a tight ESR1 protein 
regulation occurs and we confirm that ESR1 protein is also 
preserved with aging/menopause. Further, the possible 
interaction of various species of small or long non-coding 
RNAs or circular RNAs were not investigated here [33, 
34]. Indeed, the low number of protein samples and the 
potential effect of local production of E2 in adipose tissue, 
which we had no opportunity to investigate here, should 
be acknowledged as possible limitations of this work.
As far as the other validated miRs are concerned, 
miR-363-3p and miR-486-5p have previously been shown 
to be involved in adipose tissue remodeling. A study 
performed by Chen and colleagues [11] demonstrated 
that miR-363 is downregulated during adipogenic 
differentiation in the adipose tissue-derived stromal cells. 
Based on those findings, our data support that adipose 
tissue status from post-menopausal women, having the 
highest miR-363-3p expression, is likely related with 
reduced differentiation capacity. This finding is reinforced 
by the common notion that a younger tissue is more prone 
to proliferate and differentiate than older tissue. Further, 
the expression of miR-486-5p in human adipose tissue-
derived mesenchymal stem cells has been shown to induce 
replicative senescence [35]. Our study reveals that higher 
age is related with higher expression of miR-486-5p in 
adipose tissue, thereby emphasizing the possible role of 
the menopause on the cellular homeostasis or early phase 
of replicative senescence in the tissue.
To our knowledge, no previous studies has been 
focused on miR-451a expression in adipose tissue. 
Instead, the association of miR-451a with aging has been 
identified in the skeletal muscle of monkeys [36], where 
miR-451a levels were shown to be higher with higher 
age. In addition, decreased expression of miR-451a in 
non-alcoholic steatohepatitis human liver was associated 
with an increase in pro-inflammatory cytokines [37], 
suggesting its role in inflammation. In the current study, 
miR-451a was highly expressed with aging in adipose 
tissue independently of HRT use. Interestingly, a high 
age-related miR level appears to be a common trend 
shared by other metabolic organs such as the human liver, 
as recently reported [22], suggesting a causal association 
between the hormonal age-decline and the general 
increase of miRs.
MiR-16-5p and miR-223-3p are widely studied in 
different cellular models. Age-related changes of miR-16-
5p have been shown to be associated with vascular and 
neurodegenerative diseases and B-cell function [38, 39] 
whereas, with advanced age, an increase of miR-223-3p 
in inflammatory cells has been reported [40]. MiR-223-
3p was also found to regulate macrophage activation 
resulting in the suppression of pro-inflammatory responses 
in the adipose tissue of mice [41]. In the current study, 
the highest expression of both miRs was found in the 
adipose tissue of postmenopausal women without HRT, 
strengthening their association with aging. However, 
the possible contribution to the level of miR-223-3p 
of adipose tissue macrophages cannot be excluded. In 
addition, we have previously demonstrated an association 
between HRT and miR-223-3p in the skeletal muscle of 
these same postmenopausal HRT-discordant MZ twins, 
thus suggesting tissue-specific regulation of miR-233-3p 
expression [19].
ESR1 signaling pathway in adipose tissue is 
likely to be followed by the activation of AKT1, 
leading in turn to more proliferative or anti-apoptotic 
processes. AKT1 has also been previously linked 
to estrogen signaling [42]. Our results showed that 
postmenopausal women have lower amounts of AKT1 
in their subcutaneous adipose tissue than premenopausal 
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women. This age-association was consistent for both 
the mRNA and protein levels independently of HRT 
use. AKT1 affects cellular homeostasis and it is 
considered as a survival factor suppressing apoptosis. 
The role of AKT1 in human adipocytes was previously 
demonstrated [43] and authors showed that AKT1 
takes part in insulin-induced metabolic signaling. In 
the current study, the lower amount of AKT1 in the 
postmenopausal women could indicate a weakened 
sensitivity to insulin and reduced proliferative status. 
Further, E2 is able to induce BCL-2 and CCND1 in 
breast cancer cells [44] and they are downstream from 
AKT1. We showed that BCL-2, an anti-apoptotic 
protein, is less abundant with aging suggesting that the 
rate of apoptosis could be accelerated in older women. 
On the contrary, CCND1 mRNA levels were negatively 
associated with age. However, the proteins did not differ 
among the groups, suggesting a more complex post-
transcriptional regulation. The mRNA expression of 
BRAF, a molecule regulating cell growth independently 
of AKT1, did not differ among the groups. However, its 
protein was lower with higher age, suggesting, also in 
this case, further levels of regulation. These findings 
indicate lower proliferation capacity of adipose tissue 
in postmenopausal than premenopausal women being 
in line with previous studies showing sex-dependent 
differences in healthy adipose tissue remodeling [45]. 
Further, our results also support lower expression of 
anti-apoptotic mediators with postmenopausal age.
Altogether, our data indicate that menopausal 
transition acts as a crossway between apoptotic and 
proliferative signaling. Lower levels of specific proteins, 
i.e. AKT1, BCL2 and BRAF, after menopause suggest 
that the proliferative activity is likely slowed down in the 
subcutaneous adipose tissue obtained from the abdominal 
region. Based on the current findings, we can hypothesize 
that adipocytes are addressed towards deficiency in cellular 
remodeling and/or early phase of cellular senescence 
following menopause. The subcutaneous adipose tissue, 
even if not representative of all the different types of fat in 
humans, shows an age-related increase of miR expressions 
involved in the estrogen-signaling pathway.
The interplay of age, systemic E2 levels and 
tissue-specific miRs highlights the critical role of HRT 
that partially slows down the effects of menopausal 
estrogen decline in a tissue-related manner and 
specifically on miR-19a-3p. HRT is currently used by 
over 100 million women worldwide thus its application 
as an anti-aging therapy to counteract the development 
of osteoporosis, cardiovascular diseases and metabolic 
disorders and likely increasing the healthy life span 
is definitively relevant. However, longitudinal studies 
with greater numbers of participants need to confirm 
the proposed causality of the present findings and 




The current study is based on two different sample 
and data sets as presented in Figure 1A, 1B: The former 
is named: Sarcopenia and Skeletal Muscle Adaptation 
to Postmenopausal Hypogonadism: Effects of Physical 
Activity and Hormone Replacement Therapy in Older 
Women – a Genetic and Molecular Biology Study 
on Physical Activity and Estrogen- related Pathways 
(SAWEs-study). The latter is named: Circulating 
microRNAs and body composition (miRBody-study). The 
recruitment process and exclusion criteria for participation 
for both studies are also presented in the figure.
Briefly, the SAWEs-study investigated a group of 
healthy premenopausal women (n=17, 32.9 ± 3.3 years) 
with a natural menstrual cycle and no estrogen/progesterone-
based treatments for at least the previous 5 years [46] and a 
group of postmenopausal MZ twin sister pairs (n=5 pairs, 
57.4 ± 1.5 years) discordant for E2-based HRT (mean 
duration of HRT use 6.9±4.1 years) [6]. The miRBody-
study investigated 33 independent postmenopausal women 
either using estrogen-based HRT (mean duration of HRT use 
6.6±6.3 years, n=16, age 57.7±2.9 years) or not (n=17, age 
58.8±3.0 years). The study protocols were approved by the 
Ethics Committee of the Central Finland Health Care District 
(SAWEs: 7.6.2006 and 22.11.2006 E0606/06; miRBody: 
3.2.2015 1U/2015). All the study participants gave their 
written informed consent. The study was conducted 
according to the guidelines of the Declaration of Helsinki.
Participant characteristics
BMI was calculated from body weight and height 
(kg/cm2). Body fat percentage and lean body mass (LBM) 
were measured with bioelectrical impedance (inBody 
720, Biospace Co. Ltd., Seoul, Korea). Serum E2 levels 
were measured using an extraction radioimmunoassay 
(SAWEs) [6] and with solid-phase, chemiluminescent 
immunometric assay (miRBody) which was also used for 
the serum CRP and FSH measurements (Immulite 1000, 
Diagnostic Products, Los Angeles, CA, USA).
Sampling
In the SAWEs study, adipose tissue biopsies were 
obtained from below the navel by a physician with the 
needle-aspiration method. Blood traces were cleaned 
with 0.9 % NaCl and samples were snap frozen in liquid 
nitrogen and stored at -80°C until further analysis. The 
samples used in the mirBody-study were obtained from 
abdominal subcutaneous adipose tissue in the proximity 
of the navel during gynecological surgery. Samples were 
stored in All Protect Reagent (Qiagen) at -20°C until 
further analysis. All SAWEs blood samples were taken 
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between 7.00 to 9.00 am after overnight fast. Furthermore, 
the samples from the premenopausal women were 
collected during the first five days of the menstrual cycle 
to obtain the lowest E2 concentrations. Unfortunately, 
due to the varying times of the surgeries, the blood 
samples taken from the miRBody women were not taken 
under overnight fast but instead followed the routine 
standardized practices of the operating hospital. All 
blood samples, were allowed to clot for 30 min at room 
temperature before serum separation by centrifugation at 
4000 rpm. Serum samples were stored at -80°C in 0.5 ml 
aliquots until further analysis.
RNA extraction
Total RNA (~20 mg of tissue) was extracted from 
adipose biopsies with a mirVana miRNA isolation kit 
(Ambion, by Life Technologies, NY, USA) according to 
manufacturer’s protocol. One hundred μl of serum sample 
was used for the extraction of total RNA with Total RNA 
Purification kit (Norgen Biotek Corp, Thorold, Canada). 
The hemolysis has been controlled through visual 
inspection also comparing a control sample (without 
hemolysis evaluated by the ratio of miR-23a and miR-451) 
[47]. In addition, 20 fmol of spike-in cel-miR-39 (Qiagen, 
Hilden, Germany) was added to the serum samples at the 
lysis step to control for the RNA extraction efficiency. 
Recovery of the spike-in cel-miR-39 was constant with a 
mean Ct value of 16.6 ± 0.6.
MicroRNA profiling
To assess global miR expression, 10 SAWEs 
adipose tissue samples (4 premenopausal, 3 HRT users, 
3 non-users) and 13 serum samples (4 premenopausal, 5 
HRT users, 4 non-users) were screened using a TaqMan 
human MicroRNA Array A (Applied Biosystems, 
by Life Technologies, NY, USA) containing 377 of 
the most common human miR assays. MiR profiling 
protocol is described in details in Supplementary 
Materials.
Confirming the profiling results
For RT-qPCR validation, six miRs (miR-16-5p, 
miR-451a, miR-223-3p, miR-18a-5p, miR-19a-3p and 
miR-486-5p) expressed in both adipose tissue and serum 
samples across all the participants were selected from 
the profiling analyses, being not only expressed in both 
tissues, but having also opposite pattern of expression. 
In addition, miR-363 was also validated owing to its 
extreme FC in adipose tissue comparing all the groups. 
Samples from the premenopausal SAWEs women (n=9) 
and postmenopausal miRBody women (HRT: n=9, No 
HRT: n=12) were used for validation (see in details in 
Supplementary Materials).
MiR target analyses from adipose tissue
Based on the literature, previously validated 
miR targets were analyzed. SAWEs samples from the 
premenopausal women (n=12) and mirBody samples from 
the postmenopausal women (HRT; n=9, No HRT; n=12) 
were used to assess the mRNA target expressions by RT-
qPCR. The protein abundancy was analyzed by Western 
blotting (n=5/each group). RNA and protein analyses are 
described in details in Supplementary Materials.
Statistical analysis
The normal distribution of the studied variables, was 
tested by the Shapiro-Wilk test and the group comparisons 
for anthropometric, serum inflammatory markers and 
hormones were performed either with Independent 
samples T test and paired samples T test (within twin 
pairs) for parametric variables, or with Mann Whitney 
U test and Wilcoxon signed-rank test (within twin pairs) 
for non-parametric variables. The Kruskall-Wallis test for 
non-parametric variables was used for comparisons of miR 
expressions across groups. MiR profiling data with FC 
values greater than 1.9 were used in the IPA comparison 
analyses (Qiagen) and an activation Z-score greater than 2 
was considered statistically significant.
Venn diagram were obtained with http://bioinfogp.
cnb.csic.es/tools/venny/index.html. Diana tools (http://
diana.imis.athena-innovation.gr/DianaTools/index.php) 
and miRWalk (http://zmf.umm.uni-heidelberg.de/apps/
zmf/mirwalk2/) were used for identifying the common 
validated target genes of the analyzed miRs. Spearman’s 
rank correlation coefficient was used for the correlation 
analyses and R packages “gplots” and “RColor-Brewer” 
were used to create the clustered heatmap. P-values less 
than 0.05 were considered statistically significant.
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